Rapport Therapeutics logo
Rapport Therapeutics
RAPP | NASDAQ
Chart Builder DCF Calculator
$24.82
-$1.33 (-5.09%)
At close: Nov 16, 2026, 4:00 PM ET
$24.39
-$0.43 (-1.73%)
After-hours: Nov 16, 2026, 7:30 PM ET

Rapport Therapeutics Company Profile

Company profile explained

Company Profile

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Key Executives

Name Position
Abraham N. Ceesay Chief Executive Officer, President, Treasurer & Director
Cheryl Gault Chief Operating Officer
Karina Chmielewski Chief Information Officer & Head of Operations
Kathleen A. Wilkinson Chief People Officer
Troy A. Ignelzi Chief Financial Officer
Brian Corcoran Controller
Craig Wilhelmson Head of Data Management
David Bredt Founder & Chief Scientific Officer
Gregg Keaney Senior Vice President of CMC & Product Development
Jeffrey Sevigny Chief Medical Officer
Julie DiCarlo Head of Communications & Investor Relations
Steven Paul Founder & Independent Chairman
Swamy Yeleswaram Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 30, 2026 8-K Current Report
Oct 30, 2026 424B5 Filing
Oct 30, 2026 424B5 Filing
Oct 29, 2026 305B2 Filing
Oct 28, 2026 FWP Filing
Oct 28, 2026 FWP Filing
Oct 28, 2026 FWP Filing
Oct 28, 2026 FWP Filing
Oct 27, 2026 424B5 Filing
View All SEC Filings ➞
Rapport Therapeutics
Rapport Therapeutics logo
Country United States
IPO Date Jun 7, 2024
Industry Biotechnology
Sector Healthcare
Employees 84
CEO Abraham N. Ceesay

Contact Details

99 High Street Boston, Massachusetts 02110 United States

Stock Details

Ticker Symbol RAPP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002012593
CUSIP Number 75383L102
ISIN Number US75383L1026
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.